Warren Pharmaceuticals, Inc. is a privately held biotech company, incorporated in 2001 for the purpose of developing proprietary tissue-protective technologies.

Located in Westchester County, New York, 30 miles north of New York City, Warren Pharmaceuticals has pioneered the discovery and development of a novel therapeutic class of protein-based drugs named tissue protective cytokines (TPCs).  TPCs have potent protective effects that diminish and reverse the underlying cellular damage common to many significant diseases. The biological activities of TPCs are transduced through a novel tissue protective cytokine receptor identified by Warren scientists. 

Tissue Protective Cytokines may have the potential to treat such devastating illnesses and injuries as stroke, heart attack, spinal cord injury, acute macular edema, and acute kidney failure.

Warren has licensed the worldwide development and commercialization rights to the central and peripheral nervous system indications of its TPCs other than ophthalmic and diabetes to the Danish pharmaceutical company H. Lundbeck A/S.